Holen Sie sich die Stockscreener-App
75.01
0.08%
-0.06
Schlusskurs vom Vortag:
$75.07
Offen:
$74.75
24-Stunden-Volumen:
529.57K
Relative Volume:
0.44
Marktkapitalisierung:
$3.78B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.99M
KGV:
-25.03
EPS:
-2.9966
Netto-Cashflow:
$-24.94M
1W Leistung:
-2.31%
1M Leistung:
+7.26%
6M Leistung:
+44.81%
1J Leistung:
+64.28%
1-Tages-Spanne:
$73.81
$75.57
1-Wochen-Bereich:
$71.19
$79.17
52-Wochen-Spanne:
$36.93
$80.99
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Firmenname
Soleno Therapeutics Inc
Sektor
Branche
Telefon
650-213-8444
Adresse
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Vergleichen Sie SLNO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
75.01 | 3.87B | 0 | -38.99M | -24.94M | -2.9966 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2024-12-02 | Bestätigt | Robert W. Baird | Outperform |
| 2024-12-02 | Bestätigt | Stifel | Buy |
| 2024-09-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-23 | Eingeleitet | Stifel | Buy |
| 2023-11-21 | Fortgesetzt | Guggenheim | Buy |
| 2020-09-29 | Eingeleitet | Guggenheim | Buy |
| 2020-01-10 | Eingeleitet | Craig Hallum | Buy |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 - GlobeNewswire
New Clinical Data Shows VYKAT XR Improves Body Mass and Behavior in Prader-Willi Syndrome Patients - Stock Titan
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - GlobeNewswire
Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now? - Insider Monkey
11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q1 2025 Earnings Call Transcript - Insider Monkey
Soleno Therapeutics Announces Oral Presentations Featuring - GlobeNewswire
Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025 - Stock Titan
SLNO: Guggenheim Raises Price Target for Soleno Therapeutics | SLNO Stock News - GuruFocus
Guggenheim Boosts Price Target for Soleno Therapeutics (SLNO) | - GuruFocus
SLNO: Analyst Baird Maintains Outperform Rating, Raises Price Ta - GuruFocus
Oppenheimer maintains Soleno stock Outperform with $105 target - Investing.com
Soleno Therapeutics Reports Q1 2025 Results and VYKAT XR Launch - TipRanks
Earnings call transcript: Soleno Therapeutics misses Q1 2025 EPS forecast - Investing.com
Soleno Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Earnings Flash (SLNO) Soleno Therapeutics Q1 Loss $0.95 Vs. FactSet Est. Loss $0.97 - marketscreener.com
Soleno Therapeutics shares rise on VYKAT XR launch update By Investing.com - Investing.com Nigeria
Soleno Therapeutics shares rise on VYKAT XR launch update - Investing.com Australia
SOLENO THERAPEUTICS Earnings Results: $SLNO Reports Quarterly Earnings - Nasdaq
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results - The Manila Times
Soleno Therapeutics launches VYKAT XR for rare disease - Investing.com
Soleno Therapeutics Provides Update on U.S. Launch of - GlobeNewswire
Earnings call transcript: Soleno Therapeutics misses Q1 2025 EPS forecast By Investing.com - Investing.com UK
Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Exploring High Growth Tech Stocks In The US Market - simplywall.st
Prader-Willi Syndrome Market to Reach New Heights in Growth - openPR.com
LogiCare3PL Supports Commercial Launch of Soleno Therapeutics' VYKAT XR Following FDA Approval - Longview News-Journal
Soleno Launches Pill For Hyperphagia In Prader-Willi Syndrome Patients But Retail’s Unmoved - MSN
Piper Sandler raises Soleno Therapeutics stock target to $145 By Investing.com - Investing.com Nigeria
Piper Sandler raises Soleno Therapeutics stock target to $145 - Investing.com
Soleno Therapeutics (SLNO) Price Target Boosted to $145 by Piper Sandler | SLNO Stock News - GuruFocus
Capnia Inc stock soars to 52-week high, hits $74.11 By Investing.com - Investing.com India
Capnia Inc stock soars to 52-week high, hits $74.11 - Investing.com Australia
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET - The Manila Times
Soleno Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Soleno Therapeutics Launches First-Ever Earnings Call: Key Details for Q1 2025 Financial Results - Stock Titan
Soleno Therapeutics appoints CBIZ CPAs as new auditor By Investing.com - Investing.com India
How To Trade (SLNO) - news.stocktradersdaily.com
Soleno Therapeutics appoints CBIZ CPAs as new auditor - Investing.com Australia
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Geode Capital Management LLC - Defense World
Franklin Resources Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno launches Vykat xr for hyperphagia in Prader-Willi syndrome (SLNO:NASDAQ) - Seeking Alpha
Soleno Therapeutics launches FDA-approved PWS treatment By Investing.com - Investing.com South Africa
Soleno Therapeutics launches FDA-approved PWS treatment - Investing.com
Finanzdaten der Soleno Therapeutics Inc-Aktie (SLNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):